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Abstract
Background: The majority of peroxisomal matrix proteins destined for translocation into the peroxisomal lumen
are recognised via a C-terminal Peroxisomal Target Signal type 1 by the cycling receptor Pex5p. The only structure
to date of Pex5p in complex with a cargo protein is that of the C-terminal cargo-binding domain of the receptor
with sterol carrier protein 2, a small, model peroxisomal protein. In this study, we have tested the contribution of a
second, ancillary receptor-cargo binding site, which was found in addition to the characterised Peroxisomal Target
Signal type 1.
Results: To investigate the function of this secondary interface we have mutated two key residues from the
ancillary binding site and analyzed the level of binding first by a yeast-two-hybrid assay, followed by quantitative
measurement of the binding affinity and kinetics of purified protein components and finally, by in vivo
measurements, to determine translocation capability. While a moderate but significant reduction of the interaction
was found in binding assays, we were not able to measure any significant defects in vivo.
Conclusions: Our data therefore suggest that at least in the case of sterol carrier protein 2 the contribution of the
second binding site is not essential for peroxisomal import. At this stage, however, we cannot rule out that other
cargo proteins may require this ancillary binding site.
Background
Pex5p, the major import receptor for peroxisomal matrix
proteins, is known to carry folded proteins across the
peroxisomal membrane by a signal assembled shuttling
mechanism [1,2]. It has been found to recognise the type
1 Peroxisomal Targeting Signal (PTS1) - a C-terminal tri-
peptide of consensus sequence -[S/A/C]-[K/H/R]-[L/M]-
CO2
-, carried by some 40 human proteins destined for
the peroxisomal lumen. The PTS1 sequence binds to
Pex5p in an extended conformation, which is accommo-
dated in a deep cavity in the tetratricopeptide repeat
(TPR) domain of Pex5p [3,4] (Figure 1A). An additional
interface, remote from the PTS1 binding site, of about
500 Å
2 has been found to form between Pex5p and
the model cargo protein sterol carrier protein 2 (SCP2),
as demonstrated by the crystal structure and solution stu-
dies of SCP2 in complex with the C-terminal region of
Pex5p [4]. In the following we will refer to the interface
as “ancillary” or “secondary”. This interface utilises the
first and fourth a-helices of SCP2 and helices 15 and
16 from the Pex5p C-terminal helical bundle (Figure 1A
&1B) and its formation confers an increased binding
affinity of around 6-fold when compared to a minimal
PTS1 hexapeptide (PGNAKL-CO2
-), derived from the
C-terminus of SCP2 [4]. Taken together, these observa-
tions may imply the presence of an additional receptor
recognition element in SCP2, supplemental to the PTS1.
Inspection of the secondary interface of the Pex5p(C)-
SCP2 complex structure reveals several intermolecular
hydrogen bonds (Figure 1C), in particular: the carboxylate
group of Glu35 from SCP2 interacts with the side chains of
two Pex5p residues, Arg608 and Tyr620; Lys38 from SCP2
forms a salt bridge with Asp624 from Pex5p; finally, Lys28
from SCP2 interacts with the main chain carbonyl group
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apo-structure [4] reveals that in the absence of SCP2, two
residues from this interface, Arg608 and Asp624, re-orient
their sidechains to form an intramolecular salt bridge,
inducing a re-orientation of the sidechain of Tyr620 (Fig-
ure 1D). An alignment of a set of Pex5p sequences (Figure
1B) indicates that while Tyr620 and Asp624 are only partly
conserved, a basic residue at the position equivalent to
Arg608 in human Pex5p is invariant.
In this study, we have made point mutations of two
key residues of the ancillary SCP2 binding interface in
Pex5p, Arg608 and Asp624, to tryptophans to assess the
relative importance of the additional interface in the
recognition of SCP2 by Pex5p. To dissect the contribu-
tions of the PTS1 and these additional interactions, we
also used a version of SCP2 lacking the C-terminal
PTS1, for comparison. By four different approaches we
demonstrate that while receptor-cargo binding and
SCP2 transfer into the peroxisome are absolutely depen-
dent on the presence of the PTS1, the ancillary interface
is found to be dispensable - mutations effecting binding
do not inhibit peroxisomal import in vivo. These results
indicate that the ancillary interface is unlikely to play an
important role in the import of the PTS1 protein SCP2.
Figure 1 Structural features of the Pex5p-SCP2 ancillary interface. (A) Cartoon of the X-ray crystal structure of Pex5p(C) in complex with
mSCP2 [4]. Pex5p(C) is shown in green and mSCP2 in blue. A partial surface representation for mSCP2 is shown, denoting the residues of
mSCP2 that approach Pex5p(C) to < 4 Å - that is, the extended C-terminal PTS1 buried within Pex5p(C) and the ancillary helix-helix interface.
The ancillary interface is highlighted - residues contributed by mSCP2 are coloured in burgundy and those contributed by Pex5p(C) in yellow.
(B) Amino acid sequence alignment of the C-terminal 3-helix segment of Pex5p, using the standard letter code. The following colour scheme is
used: CFILMPVWY (green), HNQST (magenta), DE (red), KR (blue) and AG (yellow). The alignment was generated with CLUSTAL-W [21] and
manually adjusted, the figure generated in ALINE [22]. Positions of a-helices 15, 16 and 17 (from the human Pex5p(C)/mSCP2 crystal structure,
PDB accession 2C0L, [4]) as defined by DSSP [23] are indicated at the top of the figure. Residues marked with an arrowhead (black triangle) were
mutated in this study. Species identifiers: Tb, Trypanosoma brucei; Yl, Yarrowia lipolytica; At, Arabidopsis thaliana; Cl, Citrullus lanatus; Nt, Nicotiana
tabacum; Br, Brachydanio rerio; Cg, Cricetulus griseus; Cp, Cavia porcellus; Hs, Homo sapiens; Mm, Mus musculus; Ce, Caenorhabditis elegans; Dm,
Drosophila melanogaster; Pc, Penicillium crysogenum; Hp, Hansenula polymorpha; Pp, Pichia pastoris; Ld, Leishmania donovani; Nc, Neurospora crassa;
Rn, Rattus novegicus; Sc, Saccharomyces cerevisiae; Sp, Schizosaccharomyces pombe. The human Pex5p sequence is indicated with an asterisk (black
star). In mammalian sequences, (L) and (S) denote whether the numbering used refers to the long or short forms of Pex5p. (C) Stereo view
focusing on the ancillary interface between Pex5p(C) and mSCP2 [4]. The protein colour scheme is as in (A). Sidechains are shown for residues
at the interface. See text for details. (D) View showing the different arrangement of key Pex5p residues at the ancillary interface in the presence
(green) and absence (red) of mSCP2 [4]. See text for details. Crystal structure figures were prepared in PyMOL (http://www.pymol.org).
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Yeast two-hybrid analysis of human Pex5p interactions
with SCP2
First, we created mutant versions of the cargo-binding
domain of Pex5p (Pex5p(C), consisting of residues
315-639) and tested their capacity to interact with dif-
ferent versions of SCP2 in the yeast two-hybrid system
(Figure 2). As a control, we showed that the presence of
t h eP T S 1o fS C P 2i sap r e - r e q u i s i t ef o rb i n d i n gt o
Pex5p(C), as no interaction could be detected in its
absence, thus confirming previous findings [4]. The
introduction of the mutation R608W into Pex5p(C) did
result in a three-fold reduction of the interaction with
both pre- and mSCP2. In contrast, the Pex5p(C)
D624W mutation showed little affect, either leading to a
slight decrease (mSCP2) or increase (preSCP2) of the
interaction. To confirm that the observed decrease
with the Pex5p(C) R608W construct was not due to
problems with expression or stability of the protein, we
performed Western blotting analysis with Pex5p antibo-
dies on yeast lysates from cells expressing the different
Pex5p(C) variants. We could see that all Pex5p con-
structs were expressed at similar levels (Figure 3).
In vitro Pex5p-SCP2 binding
We tested the capacity of these mutants to bind mSCP2
in vitro using isothermal titration microcalorimetry
(ITC) (Table 1). We observed that the Pex5p(C) R608W
mutation resulted in a two fold reduction in SCP2 bind-
ing, in agreement with our yeast-two-hybrid data. In
addition, we found the binding stoichiometry reduced to
0.61, indicating that only about two-thirds of the
receptor was competent for SCP2 cargo binding, com-
pared to a value approaching one for wild-type. The
binding stoichiometry was further lowered to 0.41 when
using the second Pex5p(C) mutant, D624W, coupled
with an apparent tighter binding when compared to
wild-type Pex5p(C). Additionally, we measured the bind-
ing affinity of the Pex5p(C) mutants against a peptide
derived from the C-terminus of SCP2 (Table 1,
PGNAKL [4]), a binding event that is independent of
the ancillary interface. The Pex5p(C) R608W mutant
bound to the peptide with a similar affinity as the wild-
type protein. Furthermore, the binding stoichiometry of
this mutant was closer to that of wild-type Pex5p(C),
suggesting that the R608W mutant is impaired in bind-
ing when utilising the secondary interface but not when
using the PTS1 binding site alone.
To determine whether structural alterations induced
by the mutations were the cause of the observed binding
defects, we subjected the mutants to circular dichroism
spectropolarimetry (CD) and static light scattering (SLS)
analysis. While both mutants showed similar properties
when tested with SLS (Table 2) (i.e. they are found to
be monomeric and similarly mondispersed), a difference
could be seen with the D624W mutant using CD
(Figure 4, Table 3). Wild-type Pex5p(C) is estimated to
have 60.3 ± 2.1% a-helical content and R608W 57.0 ±
Figure 2 Summary of yeast two-hybrid data. Two-hybrid
interactions of wild-type (WT) and mutant (R608W and D624W)
forms of Pex5p(C) with SCP2. Activity of the reported gene
b-galactosidase (as defined by absorbance at 420 nm per mg of
protein per min) was used to determine the strength of interaction.
Values correspond to the mean ± SD of three independent
measurements.
*
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Figure 3 Western blot showing Pex5p wild-type and mutant
expression levels. Upper panel - Expression levels of wild-type (WT)
and mutant (R608W and D624W) forms of Pex5p in yeast cells used
for two-hybrid analysis. The Gal4AD-Pex5p(C) fusions are indicated
with a solid arrow. The open arrow indicates a breakdown product
of the fusions and the asterisk indicates a background band
recognised by the Pex5p antibody. Lower panel - Loading control,
showing the same samples above probed with the anti-hexokinase
antibody.
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residues in a-helices (as a proportion the 329 residue
fragment consistently used in crystallisation experiments)
found within the various chains of apo-human Pex5p(C)
in PDB entries 2C0M [4] and 2J9Q [5]. However, D624W
carries only 48.7 ± 1.5% a-helix (with a concomitant
increase in irregular structure), suggesting that the
D624W mutation may alter the folding properties of
Pex5p(C). These data show that a specific cargo recogni-
tion defect can be seen with the Pex5p R608W mutant
when binding full-length SCP2 and that structural
impairment was not the cause of this binding defect.
To further clarify the impaired binding between Pex5p
(C) mutants and SCP2, we examined the interaction
kinetics using the Octet RED96 assay system (Table 4)
[6]. Once again, in the absence of the PTS1, no binding
could be measured - regardless of whether the prese-
quence in SCP2 or mutations in Pex5p(C) were present.
We detected that relative to wild-type Pex5p(C), each
mutant displayed a 2.0 - 3.5 fold decreases in association
rates (kon). Most strongly impaired in kon (a 3.5 fold
decrease) was the infantile Refsum disease mutant
Pex5p(C)S600W [7], a mutation in the 7C-loop (and
therefore distant from the ancillary interface) we have
previously found not to bind to mSCP2 in ITC experi-
ments and to impair import of SCP2 and catalase
in vivo [4]. In contrast, all mutants displayed very simi-
lar dissociation rates (koff) to wild-type Pex5p(C), with
the exception of D624W, which had a 2.7 fold more
rapid koff from mSCP2 compared to wild-type. Thus, in
line with our previous data, the ancillary interface resi-
dues Arg608 and Asp624 do have roles in receptor
recognition and binding but at least in the case of
Arg608, play a lesser role in the overall stability of the
Pex5p(C)/SCP2 complex. The impaired kon and koff
demonstrated for D624W presumably result from the
structural deviation shown above.
Peroxisomal import of SCP2 in fibroblast
complementation assays
We have complemented Pex5p impaired fibroblast cul-
tures from Zellweger syndrome patient PBD005 [4] with
the long isoform of human Pex5p (Pex5p(L)) and Pex5p
(L) mutated at residues Arg608 and Asp624. 12, 24 and
48 hours after transfection, the ability of these comple-
mented cells to import the reporter molecule GFP-
mSCP2 into peroxisomes was assayed by immunofluores-
cence microscopy (Figure 5). We also determined the
localisation of Pex5p(L) using immunofluorescence. The
cytosolic distribution of Pex5p(L) was not altered by the
mutations and all ancillary interface mutants gave rise to
a similar punctuate pattern for GFP-mSCP2, characteris-
tic of peroxisomal localisation (Figure 5). Even when the
transfected cells were incubated at 40°C instead of 37°C
(to challenge the cells with a stress condition) the Pex5p
mutants retained their ability to import GFP-SCP2 into
peroxisomes (data not shown). In contrast, both negative
controls, using Pex5p(L) S600W and wild-type Pex5p(L)
with GFP-mSCP2ΔAKL, showed diffuse GFP fluores-
cence (Figure 5), indicating that in each case GFP-SCP2
is retained in the cytosol. Thus, despite the moderate
impairment of in vitro binding caused by mutation at the
ancillary interface, the same mutations do not impair
Pex5p(L) mediated peroxisomal import, at least of SCP2
as an import substrate - although subtle alterations in
import kinetics cannot entirely be excluded by our
Table 2 Summary of static light scattering data
Pex5p(C) WT Pex5p(C) R608W Pex5p(C) D624W
Molecular weight (Mw) 32.2
a (± 8%) 35.6 (± 25%) 30.3 (± 18%)
Number weighted mean (Mn) 31.0 (± 8%) 34.4 (± 20%) 29.9 (± 16%)
Polydispersity (Mw/Mn) 1.0 (± 11%) 1.0 (± 32%) 1.0 (± 25%)
Theoretical Mw 35.2 35.2 35.3
aValues are expressed in kDa.
Table 1 Summary of ITC data
Pex5p(C): Ligand n ΔH
(kJ/mol)
TΔS
(kJ/mol)
ΔG
(kJ/mol)
Kd
(nM)
Wild-type (5)
a mSCP2 0.93 ± 0.03 -43.4 -1.8 -42.3 95 ± 21
R608W (4) mSCP2 0.61 ± 0.06 -71.7 -31.8 -39.9 179 ± 19
D624W (4) mSCP2 0.41 ± 0.08 -55.6 -12.2 -43.4 45 ± 8
Wild-type (2) PGNAKL 0.94 ± 0.02 -42.5 -5.6 -36.9 547 ± 6
R608W (2) PGNAKL 0.81 ± 0.01 -51.6 -15.1 -36.5 635 ± 25
D624W (2) PGNAKL 0.49 ± 0.01 -54.7 -18.6 -36.1 763 ± 0
aNumbers in brackets indicate the number of measurements.
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and retention of the capacity of Pex5p(L) to act as a
PTS1 binding receptor are essential.
Discussion
Our data confirm previous findings [4] that the PTS1 of
SCP2 is essential for the interaction with the PTS1
receptor Pex5p and for its Pex5p-mediated targeting to
the peroxisomal matrix and we additionally characterise
the role of the secondary binding site in cargo binding.
While mutation of Arg608 in Pex5p(C) impairs the
binding affinity, stoichiometry (from two hybrid and
ITC experiments) and association rate (from Octet
RED96 experiments) with SCP2, its’ introduction in vivo
does not impair the capacity of Pex5p(L) to import
SCP2 into peroxisomes, suggesting that the ancillary
interface, formed between SCP2 and Pex5p plays only a
limited role in the import of SCP2.
The R608W and D624W mutations in Pex5p(C), while
not causing an obvious phenotype in vivo,d oc a u s e
some interesting and unexpected behaviour in vitro.
Firstly, the apparent increase in binding affinity caused
by the D624W mutation, an effect that seems to contra-
dict the reduction observed with the R608W mutant.
Our CD data indicate that the D624W mutant has
altered folding properties, in relation to the wild type
and R608W mutant, which may affect the binding to
SCP2 in an unexpected way. A reduction in binding affi-
nity can readily be justified, in terms of a loss of contact
sites in Pex5p(C). However, the reductions in binding
stoichiometries of the mutants are less easily explained.
We cannot absolutely rule out the possibility that the
Pex5p mutants are able to oligomerise, resulting in a
change in the stoichiometry of the interaction. However,
our SLS data indicate that both mutants, like the wild
type protein, are monomeric in solution, which makes
this explanation unlikely. From the Octet RED96 experi-
ments, we see that both mutants exhibit a slower asso-
ciation rate. This, together with the faster dissociation
rate observed with the D624W mutant, combined with
apparent changes in its’ folding properties, could contri-
bute to differences in the stoichiometries.
We are then left with the question as to what the pos-
sible function(s) of the secondary interface in PTS1 pro-
tein import may be. The capacity for Pex5p to import
folded proteins is well known and is likely to represent
an essential part of its task since to date no chaperones
have been identified within the peroxisomal matrix that
could aid in the folding of imported substrates. There-
fore, two possible roles for the ancillary interface could
be envisaged; increasing the overall stability of the
receptor-cargo complex by providing extra contact sites
between Pex5p and the PTS1 protein and/or a “quality
control” step, allowing Pex5p to check PTS1 proteins
for correct folding before importing them into the
matrix, since the region in SCP2 recognised by the
ancillary interface, unlike the PTS1, is fully folded. How-
ever, it may be expected that impairment of either pro-
cess would result in an inhibition of the import process,
which is not the case in our hands. Our data do not
rule out the possibility that Pex5p uses this secondary
interface with other cargo proteins and indeed, the
apparent conservation of the Arg608 residue suggests a
potential role in the function of Pex5p. In addition,
recent results indicate that other PTS1-containing pro-
teins interact with this same region of Pex5p in a similar
way (K. Fodor, personal communication). Therefore,
factors additional to the ancillary interface may deter-
mine the contribution of this binding site to cargo
recognition. Recent data indicate that human PTS1
sequences show a range of binding affinities to Pex5p
[8]. It is not hard to imagine that proteins with a rela-
tively low binding affinity may require additional contact
sites, to improve their targeting, while those with a high
binding affinity (such as SCP2) would not. The targeting
Table 3 Summary of secondary structure estimations
from CD spectropolarimetry
Pex5p(C) sample % a-helix
a % b-strand % other NRMSD
c
Wild-type 60.3 ± 1.5
b 7.0 ± 1.0 32.6 ± 0.6 0.012 ± 0.002
R608W 57.0 ± 1.0 9.0 ± 1.0 34.0 ± 0.6 0.011 ± 0.002
D624W 48.7 ± 1.5 9.0 ± 1.0 42.3 ± 0.6 0.017 ± 0.002
aSecondary structure estimates derived from DICHROWEB [17] (see Methods).
bMean and standard deviation over three measurements are given.
cNormalised root mean square deviation calculated in DICHROWEB [17].
Figure 4 Circular dichroism analysis of wild-type and mutant
Pex5p(C). CD spectra of wild-type and the mutant (R608W and
D624W) forms of Pex5p(C). While wild-type and R608W show very
similar secondary structure content, D624W does not. See text for
details.
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GFP (being a non-native import substrate commonly
used as a reporter) is not expected to interact with the
secondary interface in Pex5p, yet it is still efficiently tar-
geted, indicating that SKL is sufficient to allow targeting
in the absence of a secondary interface. Consequently,
further data on other PTS1 cargo proteins are required,
to provide insights into the role of the ancillary interface
in peroxisome translocation.
Conclusion
T h ed a t ap r e s e n t e di nt h i ss t u d yc l a r i f yt h a tt h e
mechanism of SCP2 sorting to the peroxisome is abso-
lutely PTS1 dependent but independent of the ancillary
interface. It remains to be seen if a broad set of proteins
destined for the peroxisome lumen utilise this ancillary
binding site, or if the majority rely on a more rugged
“PTS1 or nothing” selection, as appears to be the case
here.
Methods
Materials
Unless otherwise stated, all chemicals were obtained at
the highest available purity from Sigma-Aldrich. Restric-
tion enzymes were purchased from New England Bio-
labs (Ipswich, MA, USA).
Plasmids and cloning
E. coli expression vectors for the production of human
Pex5p(C) (spanning residues 315-639), preSCP2 (1-143)
and mSCP2 (21-143) complete with N-terminal His6-
GST fusion, cleavable with tobacco etch virus (TEV)
protease have been described previously [4,9]. Primers
described in [9] were also used to facilitate insertion of
the four SCP2 variants (preSCP2 (1-143), mSCP2
(21-143), preSCP2ΔAKL (1-140) and mSCP2ΔAKL
(21-140)) into pPC97 [10] between SalIa n dNotI, to
generate fusions with Gal4 DNA binding domain
(Gal4DB) for yeast two-hybrid analysis. The fusion of
HsPex5p(C) and the Gal4 activation domain (Gal4AD)
w a sm a d eb yc l o n i n gt h eNcoI-NotI fragment from the
Table 4 Summary of binding kinetics measured using Octet RED96
Immobilised biotinylated Pex5p(C) Ligand Association rate, kon (1/Ms) Dissociation rate, koff (1/s)
Wild-type mSCP2 2.3 × 10
4 (± 2.0 × 10
2) 5.5 × 10
-5 (± 2.0 × 10
-6)
Wild-type preSCP2 3.5 × 10
4 (± 2.8 × 10
2) 7.9 × 10
-5 (± 1.5 × 10
-6)
S600W mSCP2 6.5 × 10
3 (± 3.9 × 10
1) 6.0 × 10
-5 (± 1.7 × 10
-6)
S600W preSCP2 7.3 × 10
3 (± 4.8 × 10
1) 5.1 × 10
-5 (± 1.8 × 10
-6)
R608W mSCP2 7.2 × 10
3 (± 4.8 × 10
1) 7.3 × 10
-5 (± 1.8 × 10
-6)
R608W preSCP2 9.0 × 10
3 (± 6.4 × 10
1) 5.0 × 10
-5 (± 1.9 × 10
-6)
D624W mSCP2 1.1 × 10
4 (± 8.3 × 10
1) 1.5 × 10
-4 (± 2.3 × 10
-6)
D624W preSCP2 1.3 × 10
4 (± 1.1 × 10
2) 8.6 × 10
-5 (± 2.2 × 10
-6)
Figure 5 In vivo localisation assays. Subcellular localisation of
peroxisomal marker enzymes demonstrate that mutations within
the ancillary SCP2 binding site of Pex5p do not impair peroxisomal
import. Pex5p-deficient fibroblast cells were co-transfected with a
plasmid expressing GFP-SCP2 either with (A) or without its PTS1
sequence (B) and plasmids expressing wild-type (WT) or mutant
forms of Pex5p, carrying the point mutations R608W, D624W or
S600W. Forty eight hours after transfection GFP-SCP2 was visualised
by direct fluorescence (green colour), while Pex5p (A) and Pex14p
(B) were detected by immunofluorescence microscopy. Scale bars
(in bottom right micrographs) indicate 10 μM.
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mutations were introduced into the various Pex5p con-
structs using the QuikChange™ site directed mutagen-
e s i sk i t( S t r a t a g e n e )u s i n geither the Gal4AD Pex5p(C)
plasmid, the His6-GST Pex5p(C) plasmid, or the
pcDNA3 derived expression vector pGD106 [11] as tem-
plates. Details of the primers used can be seen in Table 5.
The Pex5p S600W mutant has been described previously
[4]. All constructs were confirmed by DNA sequencing.
Strains and culture conditions
Recombinant production of human Pex5p(C), preSCP2
and mSCP2 in E. coli has been described before [4,9].
The yeast strain S. cerevisiae PCY2 (MATΔ, Δgal4,
Δgal80, URA3::GAL1-lacZ, lys2-801, his3-Δ200, trp1-
Δ63, leu2, ade2-101) was used for two-hybrid analysis.
Yeast transformations were performed as described in
[12]. Transformants were grown on minimal medium
containing 0.67% yeast nitrogen base (Difco), 2% glucose
and amino acids (20 μg/ml) as required.
Yeast two-hybrid analysis and Western blotting
GAL4 based yeast two hybrid analysis was conducted as
described in [10] with b-galactosidase enzyme activity
determination being performed as in [13]. Samples of
lysates taken from the b-galactosidase assay were ana-
lysed by Western blotting for human Pex5p expression
levels. Proteins were separated on a SDS-polyacrylamide
gel and blotted onto a nitrocellulose membrane using a
semi-dry system. Antibodies used were directed against
S. cerevisiae hexokinase (generous gift of H. van der
Spek, FNWI, Amsterdam, The Netherlands) and human
Pex5p described in [14] Antibody binding was detected
with secondary antibodies labeled with IRDye 680 infra-
red dye on an Odyssey imager (LI-COR Biosciences).
Protein preparation and biotinylation
Preparation of Pex5p(C), preSCP2 and mSCP2 has been
described previously [4,9]. Mutant Pex5p(C) proteins
were prepared in a similar way as described in [4]. Pur-
ity was monitored by SDS-PAGE and mass spectrome-
try. For concentration determination, proteins were
denatured in 8 M urea and the A280 nm was measured.
Extinction coefficients were calculated using the method
of Gill and von Hippel [15]. Pex5p(C) wild-type and
mutants were biotinylated using the EZ-Link
® Sulfo-
NHS-Biotinylation Kit (Pierce) as described by the man-
ufacturer. Using the 4’-hydroxyazobenzene-2-carboxylic
acid/avidin method, between 1 and 2 moles of biotin
were found incorporated with 1 mole of Pex5p(C).
Isothermal titration microcalorimetry (ITC)
ITC was performed as described in [4]. Measurements
were conducted using a MicroCal VP-ITC using either
wild-type or mutant (R608W or D624W) forms of Pex5p
(C) titrated with either mSCP2 or a peptide derived from
the C-terminus of SCP2 [4]. The peptide, PGNAKL, was
synthesised by Sigma-Aldrich at > 95% purity.
Circular dichroism spectropolarimetry
Circular dichroism spectropolarimetry (CD) was per-
formed as described in [16] with Pex5p(C) at a concen-
tration of 2 - 5 μMi n1 0m MP o t a s s i u mP h o s p h a t e
buffer pH 7.4. Each spectrum presented is the average
of three measurements. Standard deviations in ellipticity
are shown with error bars. Spectra were background
subtracted and helical content estimated via the
DICHROWEB interface [17], using CDSSTR [18] with
the SP175 basis set of spectra.
Static light scattering
The procedure used for static light scattering (SLS) ana-
lysis is described in [19].
Octet RED96 kinetic assays
To assess the binding kinetics of Pex5p(C) wild-type and
point mutants to the four SCP2 variants, the Octet
RED96 instrument (ForteBio) was used [6]. All steps
were carried out in phosphate-buffered saline (PBS) at a
rotation rate of 1000 rpm. Streptavidin conjugated sen-
sors were hydrated for 10 minutes prior to use. The bio-
tinylated sample proteins were immobilised onto the
sensor at a concentration of 20 μg/mL. The experiment
proceeded as follows; baseline - 60 seconds, biotiny-
lated-sample loading - 300 seconds, baseline 2 - 60 sec-
onds, association - 1800 seconds and dissociation - 1800
seconds. Data were acquired and assessed using the cus-
tom ForteBio software Data Acquisition v6.2 and Data
Analysis v6.3. The data were processed with the
Savitzky-Golay filter prior to analysis. Lines of best fit
were generated locally based on a 1:1 model to deter-
mine the relative binding kinetics.
In vivo peroxisome import assays
Culturing and transfection of the Pex5p deficient human
skin fibroblast cells for Zellweger syndrome patient
PBD005 was performed as described in [4]. 12, 24 and
Table 5 PCR primers used in this study
Primer name 5’-3’ sequence
HsPex5p:
R608Wf
CATCTGGAGCACCCTGTGGTTGGCATTGTCTATGTTAGG
HsPex5p:
R608Wr
CCTAACATAGACAATGCCAACCACAGGGTGCTCCAGATG
HsPex5p:
D624Wf
CCTATGGGGCAGCCTGGGCGCGGGATCTGTC
HsPex5p:
D624Wr
GACAGATCCCGCGCCCAGGCTGCCCCATAGG
Williams et al. BMC Biochemistry 2011, 12:12
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Page 7 of 848 hours after transfection, cells were fixed onto cover
glasses with 3% formaldehyde in PBS, permeablised with
1% Triton X-100 in PBS and subjected to immunofluor-
escence microscopy. To test for temperature-sensitive
import defects, the temperature of cell culture was
shifted from 37 to 40°C for 2 days. Polyclonal rabbit anti-
bodies directed against human Pex14p are described in
[20]. Polyclonal rabbit anti-Pex5p antibodies were raised
against recombinant His6-tagged Pex5p expressed in
E. coli and purified as described previously [14]. Second-
ary antibodies were conjugated with Alexa Fluor
594 (Invitrogen). Samples were also inspected for GFP
fluorescence. All micrographs were recorded on a Zeiss
Axioplan 2 microscope with a Zeiss Plan-Apochromat
63x/1.4 oil objective and an Axiocam MR digital camera
and were processed with AxioVision 4.2 software (Zeiss).
Abbreviations
CD: Circular dichroism spectropolarimetry; GFP: green fluorescent protein;
ITC: isothermal titration calorimetry; PBS: phosphate buffered saline; PTS:
peroxisomal targeting signal; SCP2: sterol carrier protein 2; SLS: Static light
scattering; TPR: tetratricopeptide repeat.
Acknowledgements
The authors would like to thank Krisztian Fodor for sharing unpublished
results, Lise Hafkenscheid & Matt Groves for technical assistance and other
members of our labs for stimulating discussions. This work was partly
funded by a grant from the Academic Medical Center awarded to B.D., a
Rubicon Fellowship (825.08.023) from the Netherlands Organisation for
Scientific Research (NWO) awarded to C.P.W and by 3D-REPERTOIRE (EC,
LSHG-CT-2005512028), grant awarded to M.W.
Author details
1EMBL-Hamburg, c/o DESY, Notkestrabe 85, 22603 Hamburg, Germany.
2Department of Medical Biochemistry, Academic Medical Center, University
of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.
3Phylogica, 100 Roberts Road, Subiaco, 6008 WA, Australia.
4Department of
Systems Biochemistry, Institute for Physiological Chemistry, Faculty of
Medicine, Ruhr University of Bochum, 44780 Bochum, Germany.
5School of
Biomedical, Biomolecular and Chemical Sciences, MCS Building (M310),
University of Western Australia, 35 Stirling Highway, Crawley, 6009 WA,
Australia.
6ARC CoE in Plant Energy Biology, MCS Building (M316), University
of Western Australia, 35 Stirling Highway, Crawley, 6009 WA, Australia.
Authors’ contributions
Experimental data were collected and analysed by CPW, NS, CAT, MvdB,
SDvH, CSB, WS and WAS. The study was conceived and designed by CPW,
RE, WS, MW and WAS. CPW, NS, CAT, RE, CSB, BD, WS, MW and WAS
interpreted the data and prepared the manuscript. All authors read and
approved the final manuscript.
Received: 9 August 2010 Accepted: 4 March 2011
Published: 4 March 2011
References
1. Girzalsky W, Platta HW, Erdmann R: Protein transport across the
peroxisomal membrane. Biol Chem 2009, 390(8):745-751.
2. Lanyon-Hogg T, Warriner SL, Baker A: Getting a camel through the eye of
a needle: the import of folded proteins by peroxisomes. Biol Cell 2010,
102(4):245-263.
3. Gatto GJ Jr, Geisbrecht BV, Gould SJ, Berg JM: Peroxisomal targeting
signal-1 recognition by the TPR domains of human PEX5. Nat Struct Biol
2000, 7(12):1091-1095.
4. Stanley WA, Filipp FV, Kursula P, Schuller N, Erdmann R, Schliebs W,
Sattler M, Wilmanns M: Recognition of a functional peroxisome type 1
target by the dynamic import receptor pex5p. Mol Cell 2006,
24(5):653-663.
5. Stanley WA, Pursiainen NV, Garman EF, Juffer AH, Wilmanns M, Kursula P:
A previously unobserved conformation for the human Pex5p receptor
suggests roles for intrinsic flexibility and rigid domain motions in ligand
binding. BMC Struct Biol 2007, 7:24.
6. Cooper MA: Optical biosensors: where next and how soon? Drug Discov
Today 2006, 11(23-24):1061-1067.
7. Shimozawa N, Zhang Z, Suzuki Y, Imamura A, Tsukamoto T, Osumi T,
Fujiki Y, Orii T, Barth PG, Wanders RJA, et al: Functional heterogeneity of
C-terminal peroxisome targeting signal 1 in PEX5-defective patients.
Biochemical and Biophysical Research Communications 1999, 262(2):504-508.
8. Ghosh D, Berg JM: A proteome-wide perspective on peroxisome
targeting signal 1(PTS1)-Pex5p affinities. J Am Chem Soc
132(11):3973-3979.
9. Stanley WA, Versluis K, Schultz C, Heck AJ, Wilmanns M: Investigation of
the ligand spectrum of human sterol carrier protein 2 using a direct
mass spectrometry assay. Arch Biochem Biophys 2007, 461(1):50-58.
10. Chevray PM, Nathans D: Protein interaction cloning in yeast:
identification of mammalian proteins that react with the leucine zipper
of Jun. Proc Natl Acad Sci USA 1992, 89(13):5789-5793.
11. Braverman N, Dodt G, Gould SJ, Valle D: An isoform of pex5p, the human
PTS1 receptor, is required for the import of PTS2 proteins into
peroxisomes. Hum Mol Genet 1998, 7(8):1195-1205.
12. Van der Leij I, Franse MM, Elgersma Y, Distel B, Tabak HF: PAS10 is a
tetratricopeptide-repeat protein that is essential for the import of most
matrix proteins into peroxisomes of Saccharomyces cerevisiae. Proc Natl
Acad Sci USA 1993, 90(24):11782-11786.
13. Klein AT, Barnett P, Bottger G, Konings D, Tabak HF, Distel B: Recognition
of peroxisomal targeting signal type 1 by the import receptor Pex5p.
J Biol Chem 2001, 276(18):15034-15041.
14. Schliebs W, Saidowsky J, Agianian B, Dodt G, Herberg FW, Kunau WH:
Recombinant human peroxisomal targeting signal receptor PEX5.
Structural basis for interaction of PEX5 with PEX14. J Biol Chem 1999,
274(9):5666-5673.
15. Gill SC, von Hippel PH: Calculation of protein extinction coefficients from
amino acid sequence data. Anal Biochem 1989, 182(2):319-326.
16. Opalinski L, Kiel JA, Williams C, Veenhuis M, van der Klei IJ: Membrane
curvature during peroxisome fission requires Pex11. Embo J 2011,
30(1):5-16.
17. Whitmore L, Wallace BA: Protein secondary structure analyses from
circular dichroism spectroscopy: methods and reference databases.
Biopolymers 2008, 89(5):392-400.
18. Sreerama N, Woody RW: Estimation of protein secondary structure from
circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR
methods with an expanded reference set. Anal Biochem 2000,
287(2):252-260.
19. Nettleship JE, Brown J, Groves MR, Geerlof A: Methods for protein
characterization by mass spectrometry, thermal shift (ThermoFluor)
assay, and multiangle or static light scattering. Methods Mol Biol 2008,
426:299-318.
20. Will GK, Soukupova M, Hong X, Erdmann KS, Kiel JA, Dodt G, Kunau WH,
Erdmann R: Identification and characterization of the human orthologue
of yeast Pex14p. Mol Cell Biol 1999, 19(3):2265-2277.
21. Thompson JD, Higgins DG, Gibson TJ: CLUSTAL W: improving the
sensitivity of progressive multiple sequence alignment through
sequence weighting, position-specific gap penalties and weight matrix
choice. Nucleic Acids Res 1994, 22(22):4673-4680.
22. Bond CS, Schuttelkopf AW: ALINE: a WYSIWYG protein-sequence
alignment editor for publication-quality alignments. Acta Crystallogr D
Biol Crystallogr 2009, 65(Pt 5):510-512.
23. Kabsch W, Sander C: Dictionary of Protein Secondary Structure - Pattern-
Recognition of Hydrogen-Bonded and Geometrical Features. Biopolymers
1983, 22(12):2577-2637.
doi:10.1186/1471-2091-12-12
Cite this article as: Williams et al.: The Peroxisomal Targeting Signal 1 in
sterol carrier protein 2 is autonomous and essential for receptor
recognition. BMC Biochemistry 2011 12:12.
Williams et al. BMC Biochemistry 2011, 12:12
http://www.biomedcentral.com/1471-2091/12/12
Page 8 of 8